In vitro and in vivo studies of antimicrobial peptide B1CTcu5 analogs encapsulated in colon-specific microparticles against Mycobacterium tuberculosis

• Grant number: 20/16573-3
• Support Opportunities: Scholarships in Brazil - Doctorate
• Effective date (Start): June 01, 2021
• Status: Discontinued
• Field of knowledge: Biological Sciences - Microbiology - Applied Microbiology
• Principal Investigator: Fernando Rogério Pavan
• Grantee: Cesar Augusto Roque Borda
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Associated scholarship(s): 21/14603-5 - Drug discovery and design: antimicrobial peptide B1CTcu5 analogs promising against Mycobacterium tuberculosis, BE.EP.DR

Abstract

The development of new molecules is the basis of Pharmaceutical Microbiology, mainly because bacteria rapidly develop resistance to various drugs, including first-line drugs. The use of antimicrobial peptides (AMPs) has been an interesting and current area of research because these molecules are not considered drugs and generally do not generate or generate low resistance. Tuberculosis (TB) is a communicable infectious disease caused mainly by the bacillus Mycobacterium tuberculosis. According to the World Health Organization (WHO), this disease is one of the ten main causes of death in the world and the main one caused by a single infectious agent, above HIV/AIDS. The synthetic peptide B1CTcu5 has 21 amino acid residues and was originally isolated from the cutaneous secretion of Clinotarsus curtipes. This peptide showed a promising initial study against M. tuberculosis and low cytotoxicity. However, the oral administration of peptide drugs, the main route of administration of the drug, is hampered due to the instability of these molecules under severe pH conditions and the enzymatic degradability imposed by the upper portions of the gastrointestinal tract. The microencapsulation of active agents with retrograded starch (AR)/Pectin (P) mixtures is an important technological tool that allows the targeting of peptides in the colon, an organ of excellence for the absorption of biotherapeutic agents. This peptide encapsulates in specific colon microparticles and studies its potential against M. tuberculosis through its portfolio of in vitro and in vivo studies. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

ROQUE-BORDA, CESAR AUGUSTO; DA SILVA, PATRICIA BENTO; RODRIGUES, MOSAR CORREA; AZEVEDO, RICARDO BENTES; DI FILIPPO, LEONARDO; DUARTE, JONATAS L.; CHORILLI, MARLUS; VICENTE, EDUARDO FESTOZO; PAVAN, FERNANDO ROGERIO. Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria. PHARMACEUTICS, v. 13, n. 6, JUN 2021. (20/16573-3, 18/25707-3, 20/13497-4)